Aeterna Zentaris and FDA agree to SPA for Phase III endometrial cancer study
This article was originally published in Scrip
Executive Summary
Canadian drug developer Aeterna Zentaris and the US FDA have agreed to a Special Protocol Assessment (SPA) for the Quebec City-based company's upcoming Phase III clinical trial for the doxorubicin-peptide conjugate AEZS-108 in the treatment of endometrial cancer.